{"id":"https://genegraph.clinicalgenome.org/r/d501e543-4239-4b00-987e-af505fab3468v2.0","type":"EvidenceStrengthAssertion","dc:description":"*SHMT2* was first reported in relation to autosomal recessive neurodevelopmental disorder with cardiomyopathy, spasticity, and brain abnormalities (NEDCASB) in 2020 (García-Cazorla, et al., 2020, PMID:33015733). Patient fibroblasts with NEDCASB were found to have altered mitochondrial membrane potentials and ROS levels. Evidence supporting this gene-disease relationship includes case-level data and experimental data. At least 8 variants (missense and single amino acid deletion) have been reported in 5 probands from 2 publication (PMID:33015733, PMID:35398349). Variants in this gene segregated with disease in 1 additional family member. \n\nThe gene *SHMT2* encodes an enzyme that serves as the mitochondrial form of serine hydroxymethyltransferase. Specifically, the enzyme catalyzes the reversible reaction of serine and tetrahydrofolate to glycine and 5,10-methylene tetrahydrofolate within the mitochondria. This gene-disease association is further supported by its biochemical function in kinetic assays (PMID:30500180) and a knockdown drosophila model (PMID:33015733) and a knockout mouse model (PMID:29323231), which recapitulates the molecular phenotype of deficiencies in mitochondrial respiratoration but for which homozygous knock outs are embryonic lethal at day 13.5 post coitum. The gene-disease relationship is also supported by functional alteration and rescue in cell culture models (PMIDs:29452640, 29364879), which show that null SHMT2 cells show a deficiency in respiratory chain translation due to an inability to maintain formylmethionyl-tRNA pools. \n\nIn summary, there is limited evidence to support this gene-disease relationship. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship.\n\nThis gene-disease pair was originally evaluated by the Aminoacidopathy GCEP on 11/11/2022, it was updated 07/02/2024 to reasses the NM_005412.6:c.1124-4_1125delinsA variant.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/d501e543-4239-4b00-987e-af505fab3468","GCISnapshot":"https://genegraph.clinicalgenome.org/r/cf0af939-9015-47dd-bbcd-192114220334","calculatedEvidenceStrength":"Limited","changes":[{"id":"cg:classificationChange"},{"id":"cg:sopChange"},{"id":"cg:summaryChange"},{"id":"cg:otherTextChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/cf0af939-9015-47dd-bbcd-192114220334_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10011","date":"2024-07-12T16:19:10.544Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/cf0af939-9015-47dd-bbcd-192114220334_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10011","date":"2024-07-12T16:00:00.000Z","role":"Approver"}],"curationReasons":["RecurationErrorAffectingScoreorClassification"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cf0af939-9015-47dd-bbcd-192114220334_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cc4093a7-90a0-4175-b7d9-2e920c88de75_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cc4093a7-90a0-4175-b7d9-2e920c88de75","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33015733","rdfs:label":"Patient 1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":10,"allele":{"id":"https://genegraph.clinicalgenome.org/r/63814363-7713-4715-afbe-dd0d8e63c7c4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005412.6(SHMT2):c.1495C>G (p.Pro499Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA385406054"}},"detectionMethod":"Whole exome sequencing","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Axonal neuropathy. In patient fibroblasts, mitochondrial membrane potential was found to be altered, as well as ROS levels (both total and mitochondrial).","phenotypes":["obo:HP_0001639","obo:HP_0000750","obo:HP_0012664","obo:HP_0006895","obo:HP_0003487","obo:HP_0002169","obo:HP_0000252","obo:HP_0002064","obo:HP_0001348","obo:HP_0001263","obo:HP_0001319"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/07387297-eb9c-4ba6-93e3-c40523f4f932_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33015733","allele":{"id":"https://genegraph.clinicalgenome.org/r/63814363-7713-4715-afbe-dd0d8e63c7c4"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/07387297-eb9c-4ba6-93e3-c40523f4f932","type":"EvidenceLine","dc:description":"Absent from gnomAD in all subpopulations. ","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/07387297-eb9c-4ba6-93e3-c40523f4f932_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/51b1215d-013b-433b-9437-5ea706e0efbd_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/51b1215d-013b-433b-9437-5ea706e0efbd","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33015733","rdfs:label":"Patient 5","ageType":"AgeAtReport","ageUnit":"Years","ageValue":2,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/28aa2fea-fce4-43e7-a41d-6663dc9d9800","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005412.6(SHMT2):c.557C>G (p.Thr186Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA385472946"}},{"id":"https://genegraph.clinicalgenome.org/r/65f3a659-e4ce-48aa-ae5b-02e17c7d1dad","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005412.6(SHMT2):c.1135A>G (p.Asn379Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA385404605"}}],"detectionMethod":"Whole Exome sequencing","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Microretrognathism, bivid uvula, no facial movement. In patient fibroblasts, mitochondrial membrane potential was found to be altered, as well as ROS levels (both total and mitochondrial).","phenotypes":["obo:HP_0000252","obo:HP_0003781","obo:HP_0000637","obo:HP_0001508","obo:HP_0001684","obo:HP_0011344","obo:HP_0001349","obo:HP_0001631","obo:HP_0008872"],"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/b04fded6-09da-4462-9a16-5801b6a054a0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33015733","allele":{"id":"https://genegraph.clinicalgenome.org/r/65f3a659-e4ce-48aa-ae5b-02e17c7d1dad"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/bda75d9c-2966-49cd-b1e7-890cebdfd465_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33015733","allele":{"id":"https://genegraph.clinicalgenome.org/r/28aa2fea-fce4-43e7-a41d-6663dc9d9800"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/bda75d9c-2966-49cd-b1e7-890cebdfd465","type":"EvidenceLine","dc:description":"Likely pathogenic by ClinVar, absent from GnomAD. ","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bda75d9c-2966-49cd-b1e7-890cebdfd465_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/b04fded6-09da-4462-9a16-5801b6a054a0","type":"EvidenceLine","dc:description":"Likely Pathogenic by ClinVar, absent from GnomAD. ","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b04fded6-09da-4462-9a16-5801b6a054a0_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/cddc9e50-8ebe-4133-9e38-4be04795d29b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cddc9e50-8ebe-4133-9e38-4be04795d29b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33015733","rdfs:label":"Patient 3","ageType":"AgeAtReport","ageUnit":"Years","ageValue":19,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/8676ac2b-9431-404d-9695-bcab710dffe7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000012.12:g.57233745_57233750delinsA","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2695216930"}},{"id":"https://genegraph.clinicalgenome.org/r/b180afa7-645e-44c2-aac8-728c0ef5197d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005412.6(SHMT2):c.1267G>A (p.Gly423Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA6646619"}}],"detectionMethod":"Whole exome sequencing ","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Mildly increased concentric left ventricular wall thickness. In patient fibroblasts, mitochondrial membrane potential was found to be altered, as well as ROS levels (both total and mitochondrial).","phenotypes":["obo:HP_0001511","obo:HP_0010775","obo:HP_0001332","obo:HP_0031014","obo:HP_0001260","obo:HP_0008936","obo:HP_0007010","obo:HP_0012664","obo:HP_0001276","obo:HP_0002080","obo:HP_0001263","obo:HP_0000252","obo:HP_0001631","obo:HP_0033725"],"sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/7fbc160f-b93b-47bf-8932-61f1e9ca0ab3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33015733","allele":{"id":"https://genegraph.clinicalgenome.org/r/8676ac2b-9431-404d-9695-bcab710dffe7"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/a7c3ab9d-4c14-42fa-bcc9-ad5ece233ba5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33015733","allele":{"id":"https://genegraph.clinicalgenome.org/r/b180afa7-645e-44c2-aac8-728c0ef5197d"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/7fbc160f-b93b-47bf-8932-61f1e9ca0ab3","type":"EvidenceLine","dc:description":"Blood RNA sequencing revealed that this NM_005412.6:c.1124-4_1125delinsA variant results in abnormal splicing, leading to the creation of a novel splice acceptor, loss of three coding nucleotides (r.1124_1126del), and deletion of a single glycine residue (p.Gly375del).","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7fbc160f-b93b-47bf-8932-61f1e9ca0ab3_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/a7c3ab9d-4c14-42fa-bcc9-ad5ece233ba5","type":"EvidenceLine","dc:description":"Pathogenic by ClinVar, present in GnomAD 2.1.1 in the African/African American population of 0.00006159 (1/16236)\t","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a7c3ab9d-4c14-42fa-bcc9-ad5ece233ba5_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/c056301e-024a-4cd8-9b13-72423b784f70_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c056301e-024a-4cd8-9b13-72423b784f70","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33015733","rdfs:label":"Patient 4","ageType":"AgeAtReport","ageUnit":"Years","ageValue":12,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/29961ce1-331d-43a4-b505-2b6f33f6cce8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005412.6(SHMT2):c.1304A>C (p.Gln435Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA385405067"}},{"id":"https://genegraph.clinicalgenome.org/r/852476b6-823d-4d40-8c7e-78f82eda9956","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005412.6(SHMT2):c.469C>T (p.Pro157Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA385472386"}}],"detectionMethod":"Whole Exome Sequencing ","firstTestingMethod":"Exome sequencing","phenotypeFreeText":" In patient fibroblasts, mitochondrial membrane potential was found to be altered, as well as ROS levels (both total and mitochondrial).","phenotypes":["obo:HP_0001639","obo:HP_0031958","obo:HP_0002342","obo:HP_0001276","obo:HP_0000252","obo:HP_0007256","obo:HP_0001348","obo:HP_0012666","obo:HP_0001310","obo:HP_0003487","obo:HP_0002378"],"sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/94e800c3-02b9-4b07-8399-7597914a8e46_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33015733","allele":{"id":"https://genegraph.clinicalgenome.org/r/29961ce1-331d-43a4-b505-2b6f33f6cce8"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/ee098a26-ce7d-4e6a-a82d-359178abe646_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33015733","allele":{"id":"https://genegraph.clinicalgenome.org/r/852476b6-823d-4d40-8c7e-78f82eda9956"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/ee098a26-ce7d-4e6a-a82d-359178abe646","type":"EvidenceLine","dc:description":"Pathogenic by ClinVar, Found in GnomAD in the Latino population at a rate of 0.00002911 (1/34358)","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ee098a26-ce7d-4e6a-a82d-359178abe646_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/94e800c3-02b9-4b07-8399-7597914a8e46","type":"EvidenceLine","dc:description":"Pathogenic from ClinVar, absent from GnomAD. ","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/94e800c3-02b9-4b07-8399-7597914a8e46_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/78f1ff47-96f6-435a-b09a-73768fae5a75_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/78f1ff47-96f6-435a-b09a-73768fae5a75","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35398349","rdfs:label":"Majethia et al.  IV.1 ","ageType":"AgeAtReport","ageUnit":"Months","ageValue":18,"allele":{"id":"https://genegraph.clinicalgenome.org/r/9baeb324-6ac9-4d3d-a11c-69dda5d28b55","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005412.6(SHMT2):c.1133A>G (p.Asp378Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA6646591"}},"detectionMethod":"Singleton ES (Illumina, Inc., San Diego, California, USA) was performed for the proband using the Agilent SureSelect Clinical Research Exome v3 (CREv3) capture kit. Validation and segregation analysis of the variant by Sanger sequencing confirmed the presence of this variant in homozygous state in the proband and parents were found to be heterozygous carriers. ","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"high normal lactate levels (21 mg/dL; ref: 4.5–19.8 mg/dL) and elevated plasma ammonia (84 μmol/L; ref: 16-60 μmol/L). Electroencephalogram (EEG) performed at six months showed multifocal epileptiform abnormalities. Cardiac evaluation normal at 18 months. ","phenotypes":["obo:HP_0001347","obo:HP_0033725","obo:HP_0012448","obo:HP_0000252","obo:HP_0011344","obo:HP_0100827","obo:HP_0001562","obo:HP_0001257","obo:HP_0001518","obo:HP_0000463","obo:HP_0001508","obo:HP_0004840","obo:HP_0002553","obo:HP_0000586"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/88469419-9f81-4467-83d4-d8b1a43cc4c9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35398349","allele":{"id":"https://genegraph.clinicalgenome.org/r/9baeb324-6ac9-4d3d-a11c-69dda5d28b55"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/88469419-9f81-4467-83d4-d8b1a43cc4c9","type":"EvidenceLine","dc:description":"Variant is likely pathogenic by ClinVar. Found in the South Asian population in GnomAD at a rate of 0.00009800 (3/30612). ","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/88469419-9f81-4467-83d4-d8b1a43cc4c9_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/cf0af939-9015-47dd-bbcd-192114220334_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cf0af939-9015-47dd-bbcd-192114220334_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3df91539-016d-4dfa-8a3c-7bc9f33c3cdb","type":"EvidenceLine","dc:description":"The kinetics of SMHT2 have been well characterized for both forward and reverse reactions and under varying pH levels. Under a pH of 7.8, which best resembles the mitochondrial matrix, SHMT2 was found to have a Km value of just 0.45 ± 0.05, and a Kcat/Km(serine) of 1810.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/189e8a59-5b66-49b6-8852-fc1d0fa403bf","type":"Finding","dc:description":"The conversion of l-serine and tetrahydrofolate into glycine and 5,10-methylenetetrahydrofolate is the first step out of four that comprises mitochondrial one carbon metabolism. One of the downstream products from 5,10-methylenetetrahydrofolate is 10-formyl THF, which is required to produce fMet-tRNA(Met). Fibroblasts from patients with NEDCASB show a deficiency in oxidative capacity likely caused by an insufficiency in initiating mitochondrial translation due to a depletion of fMet-tRNA(Met).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30500180","rdfs:label":"Kinetic characterization of SHMT2","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/cf0af939-9015-47dd-bbcd-192114220334_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cd7e27b3-6fce-4fc3-abeb-bbc1778fa92b","type":"EvidenceLine","dc:description":"Upscored to one point given strength of evidence of SHMT2 knock out influencing overall mitochondrial respiration, mitochondrial protein synthesis, and the depletion of mitochondrial fMet-tRNAMet. As well as the ability to restore normal expression of mitochondrial proteins and fMet-tRNAMet pools with reintroduction of SHMT2 protein/cDNA. ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f2b18e62-ccf6-4f9c-91b7-a95eb60cb8d8","type":"FunctionalAlteration","dc:description":"SHMT2-null Jurkat cells demonstrated a significant reduction in basal oxygen consumption rate (69.1%), and a significant reduction in mitochondrial ATP production (68.9%). Additionally, null cells showed a significant reduction in the levels of mitochondrially encoded cytochrome c oxidase I and II and NADH-ubiquinone oxidoreductase chain 1, as well as reduced synthesis of specific mtDNA-encoded proteins. Importantly, SHMT2-null cells exhibited substantial loss of mitochondrial fMet-tRNAMet and accumulation of the non-formylated Met-tRNAMet.  Together, this experiment supports the hypothesis that phenotypes associated with SHMT2 deficiency are caused by a failure to maintain formylmethionyl-tRNA pools, which thus causes a deficiency in translation in the mitochondria.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29452640","rdfs:label":"Minton et al. functional alteration in non patient cells "}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/cf0af939-9015-47dd-bbcd-192114220334_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/eabe13eb-aaae-4a96-a298-f1686d818499","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1fe430bd-a173-482b-b3a5-7a2aa856e0e7","type":"Finding","dc:description":"Re-expression of wild-type protein, but not the catalytically inactive mutants, p.Glu98Leu/p.Tyr106Phe) or a PLP-binding mutant SHMT2 (p.Lys280Gln) rescued oxidative phosphorylation deficiency and normalized glycolytic flux. In addition, SHMT2 re-expression rescued the growth defect of SHMT2 knockout cells and normalized 1C metabolism. Results demonstrate that SHMT2 is critical to respiratory chain translation and thus oxidative phosphorylation. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29364879","rdfs:label":"Morscher et al. ","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityCellCultureRescueCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/396d994b-238a-4cce-bbc3-443d5f1f9e83","type":"EvidenceLine","dc:description":"Downscored to 1 due to a recapitulation of the disease at the molecular level, but a lack of recapitulation of the disease phenotype at the organ/organism level. Follow up paper on same knock out embryos at 13.5 post coitum by same authors (PMID: 31690790) demonstrated that the livers but not the brains presented mitochondrial respiration defects and growth retardation. Additionally, the authors found that Shmt2 deficiency induced foetal liver-specific downregulation of 1C-metabolic pathways that create taurine and nucleotides required for mitochondrial respiratory function and cell division, respectively, resulting in the manifestation of mitochondrial respiration defects and growth retardation. Fiddler et al. also demonstrated that homozygous KO mice are embryonic lethal  (PMID:34383924).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/94314fc1-bf57-4b0b-8191-5ae6eba5b325","type":"Finding","dc:description":"Model system provides evidence that SHMT2 deficiency causes deficiencies in mitochondrial respiration which the authors posit is due to deficiencies in production of N-formylmethionine-tRNA and mitochondrial translation. However, there is limited phenotype overlap between SHMT2 knock out mice and probands with SHMT2 variants, as knock out mice were embryonic lethal while probands survive at least through childhood with cardiomyopathy, spasticity,\nand brain abnormalities. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29323231","rdfs:label":"Tani et al. SHMT2 Knock Out Mice ","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/4260b6cd-a1ef-402a-9ffe-01152e1036d8","type":"EvidenceLine","dc:description":"Downscored at one point given an incomplete match between the motor deficit phenotypes of drosophila SHMT2 knock down and individuals with NEDCASB. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/96620a6f-f739-4207-bff6-b3b49c828f31","type":"Finding","dc:description":"Knock down SHMT2 drosophila shed light on potential molecular changes that could lead to the wide range of motor deficits seen in individuals with NEDCASB. The authors found that knock down drosophila showed a significant increase in satellite boutons compared to controls, accompanied by motor deficits like reduced climbing distance and velocity. While the motor deficit phenotypes found in NEDCASB such as spasticity and dystonia are impossible to fully replicate in drosophila, this study provides further evidence that SHMT2 depletion may lead to motor deficits. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33015733","rdfs:label":"Knock down SHMT2 in Drosophila motor neurons ","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":5}],"evidenceStrength":"Limited","sequence":8709,"specifiedBy":"GeneValidityCriteria10","strengthScore":6,"subject":{"id":"https://genegraph.clinicalgenome.org/r/L5He5EGT6AM","type":"GeneValidityProposition","disease":"obo:MONDO_0030866","gene":"hgnc:10852","modeOfInheritance":"obo:HP_0000007"},"version":"2.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_cf0af939-9015-47dd-bbcd-192114220334-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}